Cargando…
NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program
Neurofibromatosis Type I (NF1) is caused by variants in neurofibromin (NF1). NF1 predisposes to a variety of benign and malignant tumor types, including breast cancer. Women with NF1 <50 years of age possess an up to five-fold increased risk of developing breast cancer compared with the general p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562659/ https://www.ncbi.nlm.nih.gov/pubmed/31121919 http://dx.doi.org/10.3390/cancers11050707 |
_version_ | 1783426353147674624 |
---|---|
author | Maani, Nika Westergard, Shelley Yang, Joanna Scaranelo, Anabel M. Telesca, Stephanie Thain, Emily Schachter, Nathan F. McCuaig, Jeanna M. Kim, Raymond H. |
author_facet | Maani, Nika Westergard, Shelley Yang, Joanna Scaranelo, Anabel M. Telesca, Stephanie Thain, Emily Schachter, Nathan F. McCuaig, Jeanna M. Kim, Raymond H. |
author_sort | Maani, Nika |
collection | PubMed |
description | Neurofibromatosis Type I (NF1) is caused by variants in neurofibromin (NF1). NF1 predisposes to a variety of benign and malignant tumor types, including breast cancer. Women with NF1 <50 years of age possess an up to five-fold increased risk of developing breast cancer compared with the general population. Impaired emotional functioning is reported as a comorbidity that may influence the participation of NF1 patients in regular clinical surveillance despite their increased risk of breast and other cancers. Despite emphasis on breast cancer surveillance in women with NF1, the uptake and feasibility of high-risk screening programs in this population remains unclear. A retrospective chart review between 2014–2018 of female NF1 patients seen at the Elizabeth Raab Neurofibromatosis Clinic (ERNC) in Ontario was conducted to examine the uptake of high-risk breast cancer screening, radiologic findings, and breast cancer characteristics. 61 women with pathogenic variants in NF1 enrolled in the high-risk Ontario breast screening program (HR-OBSP); 95% completed at least one high-risk breast screening modality, and four were diagnosed with invasive breast cancer. Our findings support the integration of a formal breast screening programs in clinical management of NF1 patients. |
format | Online Article Text |
id | pubmed-6562659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65626592019-06-17 NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program Maani, Nika Westergard, Shelley Yang, Joanna Scaranelo, Anabel M. Telesca, Stephanie Thain, Emily Schachter, Nathan F. McCuaig, Jeanna M. Kim, Raymond H. Cancers (Basel) Article Neurofibromatosis Type I (NF1) is caused by variants in neurofibromin (NF1). NF1 predisposes to a variety of benign and malignant tumor types, including breast cancer. Women with NF1 <50 years of age possess an up to five-fold increased risk of developing breast cancer compared with the general population. Impaired emotional functioning is reported as a comorbidity that may influence the participation of NF1 patients in regular clinical surveillance despite their increased risk of breast and other cancers. Despite emphasis on breast cancer surveillance in women with NF1, the uptake and feasibility of high-risk screening programs in this population remains unclear. A retrospective chart review between 2014–2018 of female NF1 patients seen at the Elizabeth Raab Neurofibromatosis Clinic (ERNC) in Ontario was conducted to examine the uptake of high-risk breast cancer screening, radiologic findings, and breast cancer characteristics. 61 women with pathogenic variants in NF1 enrolled in the high-risk Ontario breast screening program (HR-OBSP); 95% completed at least one high-risk breast screening modality, and four were diagnosed with invasive breast cancer. Our findings support the integration of a formal breast screening programs in clinical management of NF1 patients. MDPI 2019-05-22 /pmc/articles/PMC6562659/ /pubmed/31121919 http://dx.doi.org/10.3390/cancers11050707 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Maani, Nika Westergard, Shelley Yang, Joanna Scaranelo, Anabel M. Telesca, Stephanie Thain, Emily Schachter, Nathan F. McCuaig, Jeanna M. Kim, Raymond H. NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program |
title | NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program |
title_full | NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program |
title_fullStr | NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program |
title_full_unstemmed | NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program |
title_short | NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program |
title_sort | nf1 patients receiving breast cancer screening: insights from the ontario high risk breast screening program |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562659/ https://www.ncbi.nlm.nih.gov/pubmed/31121919 http://dx.doi.org/10.3390/cancers11050707 |
work_keys_str_mv | AT maaninika nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram AT westergardshelley nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram AT yangjoanna nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram AT scaraneloanabelm nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram AT telescastephanie nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram AT thainemily nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram AT schachternathanf nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram AT mccuaigjeannam nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram AT kimraymondh nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram |